Black Diamond Therapeutic... (BDTX)

Black Diamond's silevertinib aims to challenge Tagrisso, offering broad EGFR mutation coverage, as key trial results are expected in late 2025.

BDTX and Cullinan advance next-gen EGFR inhibitors, but silevertinib's potential and valuation tilt momentum toward BDTX.

Here is how Black Diamond (BDTX) and Cidara Therapeutics (CDTX) have performed compared to their sector so far this year.

Black Diamond sharpens focus on silevertinib after outlicensing BDTX-4933, cutting costs, and securing cash runway into late 2027.

Black Diamond shines with a 51.1% stock surge, fueled by silevertinib's progress and pipeline momentum in oncology.

Black Diamond focuses on silevertinib for NSCLC and GBM, with key trial readouts due in late 2025 and FDA feedback expected in 2026.

Black Diamond Therapeutics' Silvertinib (BDTX-1535) targets non-classical EGFR mutations in NSCLC, addressing an unmet need left by current standard Osimertinib. Preliminary Phase 2 results for Silver...

Black Diamond (BDTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Here is how Black Diamond (BDTX) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.